Using a special dye to improve surgery for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I/II trial evaluates the safety and effectiveness of panitumumab-IRDye800, a combination of an antibody drug and an investigational dye, in enhancing the visibility of pancreatic cancer during surgery. The study aims to determine the optimal dose of the dye for identifying cancerous tissue compared to normal tissue. Patients will receive the dye before undergoing surgical resection, and advanced imaging techniques will be used to detect any remaining cancerous lesions. The trial will also assess the dye's safety and tolerability in patients with pancreatic adenocarcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
* Planned standard of care surgery with curative intent for pancreatic adenocarcinoma
* Life expectancy of more than 12 weeks
* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level =\< 1
* Hemoglobin \>= 9 gm/dL
* Platelet count \>= 100,000/mm\^3
* Magnesium \> the lower limit of normal per institution normal lab values
* Potassium \> the lower limit of normal per institution normal lab values
* Calcium \> the lower limit of normal per institution normal lab values
* Thyroid-stimulating hormone (TSH) \< 13 micro international units/mL

Exclusion Criteria:

* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment
* History of infusion reactions to panitumumab or other monoclonal antibody therapies
* Pregnant or breastfeeding
* Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females)
* Lab values that in the opinion of the physician would prevent surgical resection
* Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents

Where it's running

• Stanford University, School of Medicine
  Palo Alto, California, United States Recruiting

Study contacts

• Principal investigator: George Poultsides — Stanford University
• Study coordinator: gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
• Email: gitrialeligibility@stanford.edu
• Phone: (650) 498-7757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Targeted dual-imaging helper for head and neck cancer surgery

  This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741643

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.